Please ensure Javascript is enabled for purposes of website accessibility

Kodak Stock Up More Than 1,000% On Deal To Produce Generic Drug Ingredients

By David Butler – Jul 29, 2020 at 10:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The camera giant has been awarded a huge government loan aimed at reducing U.S. reliance on foreign pharmaceutical supply.

Eastman Kodak (KODK -0.69%), the beleaguered film company that was forced into bankruptcy as digital cameras took over the world, has found a new business entirely. The stock skyrocketed today on news that it was awarded a government loan for $765 million under the Defense Production Act to help the company begin producing generic drug ingredients.

It's a surprising turn for what was primarily a photography-based business. The deal is a play on improving America's ability to rely on domestic production of pharmaceutical products amid the coronavirus pandemic. Kodak's facilities in Rochester and St. Paul, Minnesota are the focal points of the new pharmaceutical side of the business which will be called Kodak Pharmaceutical. Kodak said it will focus on making essential ingredients that the Food and Drug Administration has identified as there being a national shortage of.

Drugs and a bottle

Image Source: Getty Images

Some analysts are questioning the move, wondering why the deal wouldn't have been given to a company already involved in the pharmaceutical industry. President Trump may have held a preference for a producer outside of the current drug regime. Political tensions have increased this week, as pharma executives and analysts react to Trump's recent executive orders that aimed to lower drug prices.

Whatever the reasoning, it's a fascinating chance for Kodak to make a new start, and investors have reacted bullishly. So far this week, the stock is up around 1,150%. The company came out of bankruptcy in 2013 and has struggled to grow over the last five years. Moving into a field like drug sales could provide a good avenue for the photography pioneer.

David Butler has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eastman Kodak Stock Quote
Eastman Kodak
KODK
$4.33 (-0.69%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.